{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T23:42:38Z","timestamp":1787010158311,"version":"build-2736575974"},"reference-count":15,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"36","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>\n                      At present, intravesical Bacillus Calmette-Guerin (BCG) immunotherapy is recommended for prophylaxis purposes after transurethral resection of bladder tumor, but has chances of recurrence. Radical cystectomy reduces the risk of recurrence in bladder cancer patients, but may have chances of postoperative complications. The objective of the study was to test the hypothesis that radical cystectomy has overtreatment and definitive BCG immunotherapy has undertreatment in intermediate or high-risk nonmuscle invasive bladder cancer patients. Data regarding biopsies, ultrasound, the computed tomography scan, adopted treatment strategy, treatment-emergent adverse effect, and a follow-up period of 312 patients with confirmed nonmuscle invasive bladder cancer (pTa, pTis, or pT1 stage; intermediate or high-risk cancer) were reviewed. Patients who had received definitive intravesical BCG immunotherapy were included in BCG group (n\u200a=\u200a210) and those who underwent radical cystectomy were included in RXC group (n\u200a=\u200a87). Clinical decision-making for treatment strategies was evaluated for both groups. Cystitis was frequently observed in all patients who received BCG immunotherapy. In RXC group, ileus was frequently observed in all patients in early days after the operation. During 2 years of the follow-up period, biopsies, ultrasound, and the computed tomography scan reported that BCG group had fewer numbers of negative cancer patients after treatment than the RXC group after surgery (\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a&lt;\u200a.0001). Total expenditure for BCG immunotherapy was higher than radical cystectomy (22,945\u200a\u00b1\u200a945\u200a\u00a5\/patient vs 17,985\u200a\u00b1\u200a545\u200a\u00a5\/patient;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u200a&lt;\u200a.0001). Definitive BCG immunotherapy had undertreatment and radical cystectomy had overtreatment for intermediate or high-risk invasive bladder cancer patients (level of evidence III).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/md.0000000000016873","type":"journal-article","created":{"date-parts":[[2019,9,5]],"date-time":"2019-09-05T05:58:08Z","timestamp":1567663088000},"page":"e16873","source":"Crossref","is-referenced-by-count":3,"title":["Definitive BCG immunotherapy versus radical cystectomy in intermediate or high-risk nonmuscle invasive bladder cancer patients"],"prefix":"10.1097","volume":"98","author":[{"given":"Xiaoming","family":"Jian","sequence":"first","affiliation":[{"name":"Department of Urology, Shidong Hospital of Yangpu District, Shanghai"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingkang","family":"Shen","sequence":"additional","affiliation":[{"name":"Department of Urology, Shidong Hospital of Yangpu District, Shanghai"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guodong","family":"Liao","sequence":"additional","affiliation":[{"name":"Department of Urology, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, China."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2019,9]]},"reference":[{"key":"R1-20230914","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.eururo.2011.07.065","article-title":"Identifying risk factors in patients with non-muscle-invasive bladder cancer: clinical implications","volume":"60","author":"Schmitz-Drager","year":"2011","journal-title":"Eur Urol"},{"key":"R2-20230914","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.eururo.2013.10.001","article-title":"International variations in bladder cancer incidence and mortality","volume":"66","author":"Chavan","year":"2014","journal-title":"Eur Urol"},{"key":"R3-20230914","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.12968\/bjon.2018.27.9.S27","article-title":"Bladder cancer: Overview and disease management. Part 1: non-muscle-invasive bladder cancer","volume":"27","author":"Anderson","year":"2018","journal-title":"Br J Nurs"},{"key":"R5-20230914","first-page":"7","article-title":"Radical cystectomy (bladder removal) against intravesical BCG immunotherapy for high-risk non-muscle invasive bladder cancer (BRAVO): a protocol for a randomised controlled feasibility study","author":"Oughton","year":"2017","journal-title":"BMJ Open"},{"key":"R6-20230914","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/j.1464-410X.2007.06912.x","article-title":"The increasing use of intravesical therapies for stage T1 bladder cancer coincides with decreasing survival after cystectomy","volume":"100","author":"Lambert","year":"2007","journal-title":"BJU Int"},{"key":"R7-20230914","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.eururo.2009.04.038","article-title":"An individual patient data meta-analysis of the long-term outcome of randomised studies comparing intravesical mitomycin C versus bacillus Calmette-Gu\u00e9rin for non-muscle-invasive bladder cancer","volume":"56","author":"Malmstrom","year":"2009","journal-title":"Eur Urol"},{"key":"R8-20230914","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.eururo.2008.07.031","article-title":"Defining early morbidity of radical cystectomy for patients with bladder cancer using a standardized reporting methodology","volume":"55","author":"Shabsigh","year":"2009","journal-title":"Eur Urol"},{"key":"R10-20230914","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.eururo.2011.10.033","article-title":"Reporting and grading of complications after urologic surgical procedures: an ad hoc EAU guidelines panel assessment and recommendations","volume":"61","author":"Mitropoulos","year":"2012","journal-title":"Eur Urol"},{"key":"R11-20230914","first-page":"665","article-title":"Clinical significance of random bladder biopsy in primary T1 bladder cancer","volume":"8","author":"Otsuka","year":"2018","journal-title":"Mol Clin Oncol"},{"key":"R12-20230914","year":"2016","journal-title":"Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA\/SUO Joint Guideline"},{"key":"R15-20230914","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s00345-009-0395-z","article-title":"Economic aspects of bladder cancer: what are the benefits and costs?","volume":"27","author":"Sievert","year":"2009","journal-title":"World J Urol"},{"key":"R16-20230914","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/362845","article-title":"Disseminated BCG: complications of intravesical bladder cancer treatment","author":"To","year":"2014","journal-title":"Cas Rep Med"},{"key":"R17-20230914","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.eururo.2011.11.011","article-title":"Should follow-up cystoscopy in bacillus Calmette-Gu\u00e9rin-treated patients continue after five tumour-free years?","volume":"61","author":"Holm\u00e4ng","year":"2012","journal-title":"Eur Urol"},{"key":"R18-20230914","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.eururo.2007.04.062","article-title":"A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27\u200amg) versus very low-dose bacillus Calmette-Guerin (13.5\u200amg) versus mitomycin C","volume":"52","author":"Ojea","year":"2007","journal-title":"Eur Urol"},{"key":"R19-20230914","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.juro.2014.09.092","article-title":"Clinical outcomes of cT1 micropapillary bladder cancer","volume":"193","author":"Willis","year":"2015","journal-title":"J Urol"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000016873","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T17:08:16Z","timestamp":1694711296000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000016873"}},"subtitle":["A retrospective study"],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":15,"journal-issue":{"issue":"36","published-online":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000016873","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9]]}}}